H.C. Wainwright analyst Raghuram Selvaraju reiterates a Buy rating and $50 price target on shares of Anavex. The company announced the total enrollment of 92 subjects in the ANAVEX2-73 EXCELLENCE Phase 2/3 study focusing on Rett syndrome patients ages 5 to 17 years, and H.C. Wainwright expects Anavex could submit blarcamesine to the FDA in Rett syndrome before the end of 2023, assuming favorable data from the EXCELLENCE trial, with possible approval and U.S. market entry in mid-2024 assuming Priority Review, the analyst tells investors in a research note.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on AVXL:
- Anavex announces exceeding enrollment target for ANAVEX2-73 EXCELLENCE trial
- Anavex Life Sciences Announces Exceeding of Enrollment Target for the ANAVEX®2-73 (blarcamesine) EXCELLENCE Phase 2/3 Rett Syndrome Clinical Trial
- Anavex price target raised to $50 from $42 at H.C. Wainwright
- Anavex appoints Grimmer to Scientific Advisory Board
- Anavex Strengthens Scientific Advisory Board with Investigator from Phase 2b/3 Alzheimer’s Trial
